PAB Stock Overview
Develops and commercializes antibody technologies for the treatment of cancer in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Patrys Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.007 |
| 52 Week High | AU$0.012 |
| 52 Week Low | AU$0.006 |
| Beta | 0.40 |
| 1 Month Change | -6.67% |
| 3 Month Change | -22.22% |
| 1 Year Change | -33.33% |
| 3 Year Change | -85.42% |
| 5 Year Change | -72.00% |
| Change since IPO | -80.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| PAB | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -12.5% | -0.2% | -1.7% |
| 1Y | -33.3% | 4.9% | 7.0% |
Return vs Industry: PAB underperformed the Australian Biotechs industry which returned 4.1% over the past year.
Return vs Market: PAB underperformed the Australian Market which returned 8.6% over the past year.
Price Volatility
| PAB volatility | |
|---|---|
| PAB Average Weekly Movement | 15.9% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in AU Market | 16.4% |
| 10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: PAB's share price has been volatile over the past 3 months.
Volatility Over Time: PAB's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | James Campbell | www.patrys.com |
Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei. The company focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain cancer.
Patrys Limited Fundamentals Summary
| PAB fundamental statistics | |
|---|---|
| Market cap | AU$16.45m |
| Earnings (TTM) | -AU$5.12m |
| Revenue (TTM) | AU$1.70m |
9.7x
P/S Ratio-3.2x
P/E RatioIs PAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PAB income statement (TTM) | |
|---|---|
| Revenue | AU$1.70m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$1.70m |
| Other Expenses | AU$6.82m |
| Earnings | -AU$5.12m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0025 |
| Gross Margin | 100.00% |
| Net Profit Margin | -302.26% |
| Debt/Equity Ratio | 0% |
How did PAB perform over the long term?
See historical performance and comparison